Become A Featured Company

Ovation: Where Science, Medicine, and Cannabis Meet

Ryan Allway

May 28th, 2021

App, Exclusive, Top News, Top Story

 

With the quickly expanding legal cannabis market finding its legs after years of prohibition, there are several hurdles remaining before the plant and its cannabis-derived product offspring are fully accepted by mainstream society. First and foremost is, of course, full legalization. From that important step everything follows, from banking regulations to changes in incarceration to consumer acceptance. But there is a factor that could serve to speed up the process – scientific research. The more cannabis is proven to be safe and controllable and effective as a medicine, the more likely it is that the powers that be will remove the last remaining barriers to a relatively free market for cannabis products.

In this regard, Ovation Science Inc. (CSE:OVAT) (OTCQB:OVATF) is a leader in the cannabis-derived products sector of the industry. The company has taken its deep pharmaceutical background and focused on developing an advanced, patented, effective, and safe cannabinoid delivery technology called Invisicare®. The system efficiently delivers active ingredients such as THC and CBD in both topical and transdermal applications. To date, Ovation has created over 30 product formulations utilizing Invisicare®. The company has its own consumer product lines Invibe®MD and Arlo CBD Beauty which it sells through its own e-commerce portals while simultaneously licensing their formulations to state operators who then manufacture and market Ovation’s formulations in their designated territory.

We recently interviewed Ovation Science CEO and Co-Founder Terry Howlett about various aspects of the company, its technology, and the market opportunities for Invisicare® products. You can see parts of the conversation here in this article:

Click here to learn more about investing in patented skincare technology

Rooted in Pharmaceutical Science

Ovation’s Head of Product Development, James Roszell, PhD, is a doctoral chemist and leads the team of researchers for the company. He has spent the better part of 20 years developing, testing, refining, and perfecting the Invisicare® technology. He is backed by a Medical Dermatology Advisory Board consisting of dermatology experts based in Canada, the United States, and the United Kingdom. Board members include the former president of the Canadian Dermatology Association, researchers whose work has been published hundreds of times, the editor of a peer-reviewed dermatology journal, and professors at esteemed universities such as Harvard, Yale, University of British Columbia, and the University of Toronto.

The goal of this Advisory Board is to reinforce the science behind its products by providing clinical, scientific, research, and strategic advice to Ovation as it continues to develop and launch Invisicare-based products. It’s a marriage of respected scientists and proven products that is just what the industry needs to achieve further validation with both regulators and consumers alike.

Skincare and Beauty Are Lucrative Markets

Cannabinoids, the active ingredients of cannabis including CBD and THC, are proliferating in topical creams and ointments throughout the world. Applications range from medicinal products meant to address arthritis and chronic pain to beauty creams meant to enhance skin elasticity and health. CBD-infused topicals are expected to reach $4.5 billion in sales by 2025, according to Cultivating Wellness, which represents a 540% increase since 2020.

Invisicare® technology addresses this explosive market by greatly enhancing the delivery of the active ingredients. One major factor issue with traditional topical products is that cannabinoids are hydrophobic – they don’t mix with water very well at all. Human bodies, meanwhile, are famously made of about 60% water. Another issue with topical applications (think sunscreen) is they tend to wear off fairly quickly, meaning that a large percentage of active ingredients don’t penetrate the skin and deliver benefits.

Ovation’s technology ensures much more complete and long lasting delivery for both topical and transdermal applications. The company tested its topical (ingredients to be delivered ON the skin) formulations against a number of leading CBD topicals. The results were staggering, with Invisicare® products demonstrating a 40% active ingredient release rate over a two hour period compared to an average of 3% for the other creams tested. Results were similar for transdermal (ingredients to be delivered THROUGH the skin; like a “patchless patch”) formulas, with Invisicare® providing an 80% penetration rate after six hours compared to 10% to 25% for other products.

What’s Next

Ovation Science is currently investigating partnerships and licensing opportunities with qualified operators in Canada and the United States. Looking to expand on its successful collaboration with its current licensee in Nevada, Ovation’s approach is to develop and produce effective Invisicare® topicals and transdermal cream formulations for licensed operators in key markets across North America and eventually the world. It’s a fairly low overhead, recurring revenue model that allows each company in the partnership to focus on what they do best. Ovation brings the science and expertise, along with its intellectual property protection, while the partner brings distribution, sales, and marketing.

In a young, formerly illegal marketplace like the cannabis industry, scientifically-backed and patented technologies like Invisicare® represent a major step toward broad acceptance. Keep an eye on Ovation Science as it spreads the word about, and the sales of, its innovative products all powered by a breakthrough delivery solution.

Click here to learn more about investing in patented skincare technology

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading